|
gptkbp:instanceOf
|
gptkb:antibiotic
carbapenem
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J01DH03
|
|
gptkbp:brand
|
gptkb:Invanz
|
|
gptkbp:CASNumber
|
gptkb:153832-46-3
|
|
gptkbp:category
|
gptkb:antibiotic
|
|
gptkbp:chemicalFormula
|
gptkb:C22H25N3O7S
|
|
gptkbp:contraindication
|
hypersensitivity to carbapenems
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ertapenem
|
|
gptkbp:KEGGID
|
D04025
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
|
|
gptkbp:MedlinePlusID
|
a602011
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
475.52 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Pseudomonas_aeruginosa
gptkb:Acinetobacter_species
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
85-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
gptkb:DB00303
149596
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
rash
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:synonym
|
gptkb:MK-0826
gptkb:Invanz
|
|
gptkbp:UNII
|
82ZCD1D34N
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:Invanz
|
|
gptkbp:bfsLayer
|
5
|